

**Contact**

Alexandra Fuchs, PhD, COO

[afuchs@cytoo.com](mailto:afuchs@cytoo.com), +33 (0)4 38 88 47 07

**For Immediate Release**

23<sup>rd</sup>, September 2013

Press Release

## **CYTOO's 2D+ and 3D+ Cell Culture Platform at MipTec 2013 (Sept 24-26, Switzerland)**

**Grenoble, France, 23<sup>rd</sup> September 2013** – CYTOO, a life science systems & tools company providing disruptive solutions for cell-based assays and High Content Screening (HCS), will attend the MipTec 2013 conference in Basel, Switzerland. The company will present the 2D+ and 3D+ Cell Culture Platforms, opening fresh perspectives for cell based assay development in drug discovery.

2D+ Technology is based on CYTOO's adhesive micropatterns in 96-well plates which guide cell architecture and behaviour. It addresses a major concern with traditional 2D culture, in which cells spread and move in an uncontrolled manner, introducing a considerable but unnoticed variability in cell function. By defining the 2D topology of cell adhesion, the 2D+ Cell Culture Platform enables fine control of the spreading and 3D shape of cultured cells in single- or multi-cellular configurations. This approach results in control of cell contractility, cell polarity, organelle positioning, and cell division axis.

The 3D+ Cell Culture is the new generation of 3D technologies. It enables short and long-term assays: hundreds of identical structures can be grown in an in vivo-like microenvironment and in microplate format, which facilitates the identification and quantification of even rare phenotypes. Micropatterned acini cultures can quickly and conveniently be created with any epithelial immortalized cell line or primary cells that have the capacity to form polarized acini in a 3D matrix.

The 3D+ Cell Culture is a simple method to screen drugs in a polarized and 3D automation context. It opens new perspectives in oncology, in the understanding of lumen initiation and in the approach of several conditions such as ciliopathies, gene mutations and diabetes.

During MipTec, CYTOO will be Gold Sponsor for the *Stem Cells in Biomedicine* Scientific Forum, held on September 24. Sébastien Degot, Senior R&D Scientist, will then present the "Phenotypic profiling using probabilistic density maps generated from micropatterned cells".

During the Thermo Scientific Industrial Symposium, held on September 26, he will also present the "advantages of CYTOO's 2D+/3D+ Cell Culture Platform for the imaging and analysis of complex cell models: assessment using the Thermo Scientific Cellomics CellInsight".

**Attendees are invited to visit booth #D23 to discuss their application with Mathieu Raul (Business Development Manager), Sébastien Degot (Senior R&D Scientist) and Séverine Tamas-Lhoustau (European Sales Manager).**

For more information, visit [www.cytoo.com/MipTec2013/](http://www.cytoo.com/MipTec2013/)

**Contact**

Alexandra Fuchs, PhD, COO

[afuchs@cytoo.com](mailto:afuchs@cytoo.com), +33 (0)4 38 88 47 07

**Press Release**

**About CYTOO S.A.**

CYTOO is a distinctive life sciences systems & tools company offering disruptive solutions for cell-based assays and High Content Screening (HCS) that reinforce robustness, sensitivity and powerful quantification. The Company's 2D+/3D+ Cell Culture Platform and Custom Solutions are based on adhesive micropatterns, offering control over the cells' microenvironment, leading to normalized cell morphology and behavior. The technology allows the optimization or resurrection of complex or difficult cell-based assays and enables innovative assay development.

For more information about the complete product portfolio, visit [www.cytoo.com](http://www.cytoo.com)

**Additional Contacts****CYTOO SA**

[mraul@cytoo.com](mailto:mraul@cytoo.com)

**Follow us**